<DOC>
	<DOCNO>NCT01196065</DOCNO>
	<brief_summary>This open-label , fixed sequence , two-period study assess effect memantine pharmacokinetics , safety tolerability single oral dose RO5313534 effect RO5313534 safety tolerability steady-state memantine . Healthy volunteer receive single oral dose RO5313534 Day 1 Treatment Period 1 ( 3 day ) . After washout period 5-21 day , oral memantine administer Days 1-21 Treatment Period 2 single dose RO5313534 Day 19 . There follow-up 3-4 week last dose . Anticipated time study volunteer 14 week .</brief_summary>
	<brief_title>A Study Effect Memantine Pharmacokinetics , Safety Tolerability Single Dose RO5313534 Healthy Volunteers , Effect RO5313534 Safety Tolerability Steady State Memantine</brief_title>
	<detailed_description />
	<mesh_term>Memantine</mesh_term>
	<criteria>Healthy male female , 18 45 year age inclusive Body mass index ( BMI ) 1830 kg/m2 Male subject must agree use barrier method contraception first dose end study Female subject must either surgically sterile agree use two form contraception end study Nonsmoker least 6 month Clinically significant history detection medical interview/physical examiation disease condition capable alter absorption . metabolism elimination drug , would constitute risk factor take study drug History drug addiction alcohol abuse Any confirm significant allergic reaction drug , multiple allergy judgement investigator Positive serology hepatitis B hepatitis C Human Immunodeficiency Viruses ( HIV type 1 2 ) screening Pregnant lactate woman Participation investigational drug device study within last 3 month prior first dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>